Research Analysts Offer Predictions for ACAD FY2028 Earnings

ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD) – Equities researchers at HC Wainwright upped their FY2028 earnings per share estimates for shares of ACADIA Pharmaceuticals in a research report issued on Monday, December 15th. HC Wainwright analyst A. Ghosh now forecasts that the biopharmaceutical company will earn $3.12 per share for the year, up from their prior estimate of $2.74. HC Wainwright currently has a “Buy” rating and a $37.00 target price on the stock. The consensus estimate for ACADIA Pharmaceuticals’ current full-year earnings is $0.70 per share. HC Wainwright also issued estimates for ACADIA Pharmaceuticals’ FY2029 earnings at $3.27 EPS.

ACADIA Pharmaceuticals (NASDAQ:ACAD) last posted its earnings results on Wednesday, November 5th. The biopharmaceutical company reported $0.42 EPS for the quarter, beating analysts’ consensus estimates of $0.14 by $0.28. The company had revenue of $278.63 million for the quarter, compared to analysts’ expectations of $276.52 million. ACADIA Pharmaceuticals had a net margin of 24.94% and a return on equity of 14.61%. ACADIA Pharmaceuticals’s revenue for the quarter was up 11.3% compared to the same quarter last year. During the same quarter in the prior year, the company posted $0.20 earnings per share.

A number of other analysts have also issued reports on the company. Needham & Company LLC boosted their target price on ACADIA Pharmaceuticals from $28.00 to $29.00 and gave the company a “buy” rating in a research report on Thursday, November 6th. Stifel Nicolaus set a $37.00 price objective on ACADIA Pharmaceuticals in a research note on Tuesday. Piper Sandler set a $37.00 target price on ACADIA Pharmaceuticals in a research note on Tuesday. Royal Bank Of Canada lowered their target price on ACADIA Pharmaceuticals from $34.00 to $32.00 and set an “outperform” rating for the company in a report on Thursday, November 6th. Finally, Wall Street Zen upgraded shares of ACADIA Pharmaceuticals from a “hold” rating to a “buy” rating in a research note on Saturday, November 8th. One investment analyst has rated the stock with a Strong Buy rating, twelve have issued a Buy rating, seven have issued a Hold rating and one has issued a Sell rating to the stock. According to data from MarketBeat, the company has an average rating of “Moderate Buy” and an average price target of $29.95.

ACADIA Pharmaceuticals Stock Performance

ACADIA Pharmaceuticals stock opened at $26.93 on Thursday. The company’s 50 day simple moving average is $23.59 and its 200-day simple moving average is $23.32. ACADIA Pharmaceuticals has a 1 year low of $13.40 and a 1 year high of $27.73. The company has a market capitalization of $4.56 billion, a price-to-earnings ratio of 17.37, a price-to-earnings-growth ratio of 7.26 and a beta of 0.67.

Insiders Place Their Bets

In other ACADIA Pharmaceuticals news, Director James M. Daly sold 30,000 shares of the stock in a transaction dated Monday, November 10th. The stock was sold at an average price of $22.37, for a total value of $671,100.00. Following the sale, the director owned 4,041 shares of the company’s stock, valued at $90,397.17. This trade represents a 88.13% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. Also, EVP Mark C. Schneyer sold 10,262 shares of the business’s stock in a transaction dated Tuesday, November 18th. The stock was sold at an average price of $23.69, for a total value of $243,106.78. Following the transaction, the executive vice president directly owned 53,338 shares of the company’s stock, valued at approximately $1,263,577.22. This represents a 16.14% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. Insiders have sold a total of 44,346 shares of company stock worth $1,010,957 in the last quarter. 26.50% of the stock is owned by company insiders.

Institutional Investors Weigh In On ACADIA Pharmaceuticals

Large investors have recently modified their holdings of the company. Cetera Investment Advisers acquired a new stake in shares of ACADIA Pharmaceuticals in the 1st quarter valued at $197,000. PNC Financial Services Group Inc. lifted its holdings in ACADIA Pharmaceuticals by 545.8% during the 1st quarter. PNC Financial Services Group Inc. now owns 5,438 shares of the biopharmaceutical company’s stock worth $90,000 after buying an additional 4,596 shares during the last quarter. Invesco Ltd. lifted its holdings in ACADIA Pharmaceuticals by 42.8% during the 1st quarter. Invesco Ltd. now owns 731,576 shares of the biopharmaceutical company’s stock worth $12,151,000 after buying an additional 219,256 shares during the last quarter. HighTower Advisors LLC acquired a new position in shares of ACADIA Pharmaceuticals during the 1st quarter worth about $445,000. Finally, Russell Investments Group Ltd. increased its holdings in shares of ACADIA Pharmaceuticals by 22.0% in the 1st quarter. Russell Investments Group Ltd. now owns 241,323 shares of the biopharmaceutical company’s stock valued at $4,008,000 after acquiring an additional 43,523 shares during the last quarter. 96.71% of the stock is owned by hedge funds and other institutional investors.

About ACADIA Pharmaceuticals

ACADIA Pharmaceuticals Inc, a biopharmaceutical company, focuses on the development and commercialization innovative medicines that address unmet medical needs in central nervous system (CNS) disorders and rare diseases in the United States. The company offers NUPLAZID (pimavanserin) for the treatment of hallucinations and delusions associated with Parkinson's disease psychosis; and DAYBUE, a novel synthetic analog of the amino-terminal tripeptide of insulin-like growth factor 1 for treatment of Rett Syndrome.